Evidence map›Paper›PMID 41163844›Full record

ArticleRSC advances2025

Structure-based design, synthesis, and biological activity evaluation of chalcone-piperazine derivatives as dual AChE and MAO B inhibitors.

Berkant Kurban, Begüm Nurpelin Sağlık Özkan, Derya Osmaniye, Serkan Levent, Yusuf Özkay, Zafer Asım Kaplancıklı

Erratum issuedAbstract read
In one paragraph

Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Berkant KurbanDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Afyonkarahisar Health Sciences University 03030 Afyonkarahisar Turkey.ORCID https://orcid.org/0000-0002-1595-3870
Begüm Nurpelin Sağlık ÖzkanDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University 26470 Eskişehir Turkey zakaplan@anadolu.edu.tr.ORCID https://orcid.org/0000-0002-0151-6266
Derya OsmaniyeDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University 26470 Eskişehir Turkey zakaplan@anadolu.edu.tr.ORCID https://orcid.org/0000-0002-0499-436X
Serkan LeventCentral Research Laboratory (MERLAB), Faculty of Pharmacy, Anadolu University 26470 Eskişehir Turkey.ORCID https://orcid.org/0000-0003-3692-163X
Yusuf ÖzkayDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University 26470 Eskişehir Turkey zakaplan@anadolu.edu.tr.ORCID https://orcid.org/0000-0001-8815-153X
Zafer Asım KaplancıklıDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University 26470 Eskişehir Turkey zakaplan@anadolu.edu.tr.ORCID https://orcid.org/0000-0003-2252-0923

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of pharmaceutical compounds for the treatment of Alzheimer's Disease (AD) and other neurodegenerative diseases is crucial, as the pathophysiology of AD remains incompletely understood and effective treatments are still lacking. In this study, a series of novel compounds based on Donepezil, incorporating piperazine and chalcone structures, were designed, synthesized, and characterized. The structures of the compounds were confirmed using IR,

Identifiers

PMID41163844
PMCPMC12560751

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.